Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MAXXON, INC (MXON.Nasdaq BB) Disposable syringe technology -- Ignore unavailable to you. Want to Upgrade?

To: bcjt who wrote (91)	11/18/1999 12:24:00 PM
From: bcjt	Read Replies (1) \| Respond to of 105

Thursday November 18, 6:03 am Eastern Time Company Press Release Maxxon Announces UTEK Corp. Engaged to Identify Potential Synergistic Technology Acquisitions TULSA. Okla.--(BW HealthWire)--Nov. 18, 1999--Maxxon, Inc. (OTCBB: MXON - news) and UTEK Corporation today jointly announced that Maxxon has engaged UTEK to identify potential technology acquisitions that would be synergistic with its safety syringe technology currently under development. Under the terms of the agreement, UTEK will identify and review potential university and government laboratory sources for new medical devices that are synergistic with the Maxxon syringe. According to Dr. Clifford M. Gross, UTEK's CEO, ``We are delighted to consummate this Agreement with Maxxon, Inc., as it will increase the opportunity for us to assist Maxxon in strengthening its core technology.' According to Gifford Mabie, Maxxon's President: ``Maxxon is very pleased to consummate this Agreement. We believe the UTEK team has the expertise necessary to help us identify compatible technologies to expand our strategic advantage in the medical device marketplace.' Maxxon is a development-stage corporation which owns the exclusive worldwide rights to a proprietary safety syringe and related technology. Currently there is no economical safety syringe commercially available to the world medical community. Maxxon has funded the development of the vacuum-operated safety syringe, which has reached the prototype stage. Completion of the project now hinges on the refinement of the manufacturing process and subsequent FDA approval. UTEK is a leading technology merchant that acquires and finances university-based intellectual capital for technology firms. For more information on UTEK, please visit their web site at www.utekcorp.com. This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that all forward-looking statements involve risks and uncertainties, including, without limitation, the ability of Maxxon, Inc. to accomplish its stated plan of business. Although Maxxon believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by Maxxon or any other person that the objectives and plans of Maxxon will be achieved. bcjt